MRI-Based Brain Volumetry at a Single Time Point Complements Clinical Evaluation of Patients With Multiple Sclerosis in an Outpatient Setting

Overview

Journal Front Neurol

Specialty Neurology

Date 2018 Aug 25

PMID 30140245

Citations 10

Authors

Alaleh Raji

Ann-Christin Ostwaldt

Roland Opfer

Per Suppa

Lothar Spies

Gerhard Winkler

Affiliations

Soon will be listed here.

Abstract

Thalamic atrophy and whole brain atrophy in multiple sclerosis (MS) are associated with disease progression. The motivation of this study was to propose and evaluate a new grouping scheme which is based on MS patients' whole brain and thalamus volumes measured on MRI at a single time point. In total, 185 MS patients (128 relapsing-remitting (RRMS) and 57 secondary-progressive MS (SPMS) patients) were included from an outpatient facility. Whole brain parenchyma (BP) and regional brain volumes were derived from single time point MRI T1 images. Standard scores (z-scores) were computed by comparing individual brain volumes against corresponding volumes from healthy controls. A z-score cut-off of -1.96 was applied to separate pathologically atrophic from normal brain volumes for thalamus and whole BP (accepting a 2.5% error probability). Subgroup differences with respect to the Symbol Digit Modalities Test (SDMT) and the Expanded Disability Status Scale (EDSS) were assessed. Except for two, all MS patients showed either no atrophy (group 0: 61 RRMS patients, 10 SPMS patients); thalamic but no BP atrophy (group 1: 37 RRMS patients; 18 SPMS patients) or thalamic and BP atrophy (group 2: 28 RRMS patients; 29 SPMS patients). RRMS patients without atrophy and RRMS patients with thalamic atrophy did not differ in EDSS, however, patients with thalamus and BP atrophy showed significantly higher EDSS scores than patients in the other groups. MRI-based brain volumetry at a single time point is able to reliably distinguish MS patients with isolated thalamus atrophy (group 1) from those without brain atrophy (group 0). MS patients with isolated thalamus atrophy might be at risk for the development of widespread atrophy and disease progression. Since RRMS patients in group 0 and 1 are clinically not distinguishable, the proposed grouping may aid identification of RRMS patients at risk of disease progression and thus complement clinical evaluation in the routine patient care.

Citing Articles

Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.

Leussink V, Jankovic M, Groth M, Schuh K, Schwab Sauerbeck I, Hoffmann O Brain Behav. 2024; 14(6):e3548.

PMID: 38841819 PMC: 11154816. DOI: 10.1002/brb3.3548.

Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence.

Mendelsohn Z, Pemberton H, Gray J, Goodkin O, Carrasco F, Scheel M Neuroradiology. 2022; 65(1):5-24.

PMID: 36331588 PMC: 9816195. DOI: 10.1007/s00234-022-03074-w.

Automatic segmentation of the thalamus using a massively trained 3D convolutional neural network: higher sensitivity for the detection of reduced thalamus volume by improved inter-scanner stability.

Opfer R, Kruger J, Spies L, Ostwaldt A, Kitzler H, Schippling S Eur Radiol. 2022; 33(3):1852-1861.

PMID: 36264314 PMC: 9935653. DOI: 10.1007/s00330-022-09170-y.

Predictive MRI Biomarkers in MS-A Critical Review.

Tiu V, Enache I, Panea C, Tiu C, Popescu B Medicina (Kaunas). 2022; 58(3).

PMID: 35334554 PMC: 8949449. DOI: 10.3390/medicina58030377.

A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis.

Ruggieri S, Petracca M, De Giglio L, De Luca F, Gianni C, Gurreri F J Neurol. 2021; 268(12):4698-4706.

PMID: 33942160 PMC: 8563557. DOI: 10.1007/s00415-021-10576-9.

References

Schippling S, Ostwaldt A, Suppa P, Spies L, Manogaran P, Gocke C . Global and regional annual brain volume loss rates in physiological aging. J Neurol. 2017; 264(3):520-528. DOI: 10.1007/s00415-016-8374-y. View

Popescu V, Agosta F, Hulst H, Sluimer I, Knol D, Sormani M . Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84(10):1082-91. DOI: 10.1136/jnnp-2012-304094. View

Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer M . Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol. 2013; 34(10):1931-9. PMC: 7965442. DOI: 10.3174/ajnr.A3503. View

Vaneckova M, Kalincik T, Krasensky J, Horakova D, Havrdova E, Hrebikova T . Corpus callosum atrophy--a simple predictor of multiple sclerosis progression: a longitudinal 9-year study. Eur Neurol. 2012; 68(1):23-7. DOI: 10.1159/000337683. View

Huppertz H, Kroll-Seger J, Kloppel S, Ganz R, Kassubek J . Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage. 2009; 49(3):2216-24. DOI: 10.1016/j.neuroimage.2009.10.066. View

Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach I, Bucci M . Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014; 76(4):568-80. PMC: 5316412. DOI: 10.1002/ana.24241. View

Schoonheim M, Hulst H, Brandt R, Strik M, Wink A, Uitdehaag B . Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. Neurology. 2015; 84(8):776-83. DOI: 10.1212/WNL.0000000000001285. View

Shattuck D, Mirza M, Adisetiyo V, Hojatkashani C, Salamon G, Narr K . Construction of a 3D probabilistic atlas of human cortical structures. Neuroimage. 2007; 39(3):1064-80. PMC: 2757616. DOI: 10.1016/j.neuroimage.2007.09.031. View

Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K . Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage. 2008; 40(2):570-582. PMC: 2478641. DOI: 10.1016/j.neuroimage.2007.12.035. View

10.

Gelineau-Morel R, Tomassini V, Jenkinson M, Johansen-Berg H, Matthews P, Palace J . The effect of hypointense white matter lesions on automated gray matter segmentation in multiple sclerosis. Hum Brain Mapp. 2011; 33(12):2802-14. PMC: 5435105. DOI: 10.1002/hbm.21402. View

11.

Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer M . Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol. 2011; 259(1):139-46. DOI: 10.1007/s00415-011-6147-1. View

12.

Maldjian J, Laurienti P, Kraft R, Burdette J . An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003; 19(3):1233-9. DOI: 10.1016/s1053-8119(03)00169-1. View

13.

Datta S, Staewen T, Cofield S, Cutter G, Lublin F, Wolinsky J . Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data. Mult Scler Relat Disord. 2015; 4(2):124-36. PMC: 4366621. DOI: 10.1016/j.msard.2015.01.004. View

14.

Tauhid S, Neema M, Healy B, Weiner H, Bakshi R . MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. J Neurol Sci. 2014; 346(1-2):250-4. DOI: 10.1016/j.jns.2014.08.047. View

15.

Losy J . Is MS an inflammatory or primary degenerative disease?. J Neural Transm (Vienna). 2013; 120(10):1459-62. PMC: 3779312. DOI: 10.1007/s00702-013-1079-9. View

16.

Wang C, Beadnall H, Hatton S, Bader G, Tomic D, Silva D . Automated brain volumetrics in multiple sclerosis: a step closer to clinical application. J Neurol Neurosurg Psychiatry. 2016; 87(7):754-7. PMC: 4941129. DOI: 10.1136/jnnp-2015-312304. View

17.

Houtchens M, Benedict R, Killiany R, Sharma J, Jaisani Z, Singh B . Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007; 69(12):1213-23. DOI: 10.1212/01.wnl.0000276992.17011.b5. View

18.

Audoin B, Davies G, Finisku L, Chard D, Thompson A, Miller D . Localization of grey matter atrophy in early RRMS : A longitudinal study. J Neurol. 2006; 253(11):1495-501. DOI: 10.1007/s00415-006-0264-2. View

19.

Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N . MRI as a marker for disease heterogeneity in multiple sclerosis. Neurology. 2005; 65(7):1071-6. DOI: 10.1212/01.wnl.0000178984.30534.f9. View

20.

van Munster C, Uitdehaag B . Outcome Measures in Clinical Trials for Multiple Sclerosis. CNS Drugs. 2017; 31(3):217-236. PMC: 5336539. DOI: 10.1007/s40263-017-0412-5. View